Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With HER2 Negative Locally Advanced, Recurrent or Metastatic Gastric, Oesophageal or Oesogastric Junction Adenocarcinoma

NCT05476796 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT05476796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05476796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With HER2 Negative Locally Advanced, Recurrent or Metastatic Gastric, Oesophageal or Oesogastric Junction Adenocarcinoma
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 23, 2023
Completion date
December 31, 2026
Enrollment
118 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

esophagus adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma